Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive ...

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

What if there is another road to knee recovery, a less invasive one with a faster route to getting back to doing the things ...

Mesoblast’s achievement in winning approval for its Ryoncil drug in the US in December heralds the arrival of a new class of ...

This story first appeared in Colorado Newsline. Coloradans will soon be able to take psychedelic mushrooms in a regulated ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

Rick Stewart, Chief Executive Officer of Achieve, along with other members of senior management, will provide an overview of ...

After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.